Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Postoperative Cognitive Dysfunction in Elderly
NCT02923128Phase 4Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in postoperative delirium (POD) and Post-operative cognitive dysfunction (POCD) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of postoperative delirium at 7 days. Started Nov 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative delirium (POD)Post-operative cognitive dysfunction (POCD)
Beyond the preview
Go deeper on NCT02923128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923128.